Purchase this article with an account.
Claudia Acosta, Carolina Sardi, Juan Fernando Pelaez; CENTRAL CHOROIDAL THICKNESS MEASURED BY EDI OCT IN SUBJECTS UNDER CHRONIC TREATMENT WITH INTRAVITREAL ANTI-VEGF.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):244.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To measure macular choroidal thickness (CT) and describe EDI OCT characteristics in patients with Neovascular AMD who underwent multiple intravitreal injections of anti-VEGF agents, and to compare it with Early AMD eyes, and healthy eyes,
This is an age-matched, sex-matched, case-control, cross-sectional study. A total of 74 eyes of 58 patients were evaluated. 21 eyes with Neovascular AMD and chronic anti-angiogenic intravitreal treatment (>10 injections in a 30 month period), 21 eyes with Early AMD and 32 eyes of healthy volunteers underwent SD-OCT (RTVue) with EDI technique. The average choroidal thickness (CT) was compared with the average CT value of an (age-matched, sex-matched), early AMD group and a healthy control group. A description of the morphological findings was done. Univariate linear regression analyses were perform to evaluate choroidal thickness with age, gender, BCVA and AMD diagnosis and treatment.
After controlling for age differences the number of Anti VEGF injections showed no statistically significant correlation with macular choroidal thickness (P=0,689). Among different covariates age was associated with CT (P<0.05) only in the healthy patients group, gender showed not significant association with CT in AMD groups, it was statistically significant only on the healthy group (P= 0.008). There was a difference in CT in the three groups but it was not statistically significant (P=0.064), it only show a significant difference (P<0.001) between the Early AMD and the healthy group Healthy subjects had significant thicker Choridal Measurements (234.9 μc CI 95%= 201.5- 268.2) than the other 2 groups; Patients of Neoavascular AMD showed thicker choroids (175.07 μc CI 95% =139.3-210.8) compared with Early AMD (126.3μc CI 95%= 94.9-157.6). The macular CT value was uneven in patients with Neoavascular AMD, but it was even in patients with Early AMD and healthy subjects, showing a linear distribution.
We found no correlation between the number anti VEGF injections and CT, it support the concept that anti-VEGF applications do not affect CT. In accordance to what other studies had indicated. In Healthy subjects macular CT value in patients with ages between 75-91 years is significant lower than macular CT value describe in other studies, there is not know the expected CT value for this age group, and other studies are needed.
This PDF is available to Subscribers Only